Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERMIONE-7
2019-000510-11Phase 2Terminated
- Sponsor
- University of Milano-Bicocca
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib, letrozole, anastrozole and fulvestrant in breast cancer, sponsored by University of Milano-Bicocca. Primary endpoint: Clinical benefit rate. Started Jun 2021; status: terminated.
02
Drugs
abemaciclibletrozoleanastrozolefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-000510-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000510-11.